Antiangiogenic therapy for ischemic retinopathies

Area of Science:

• Ophthalmology
• Angiogenesis Research
• Vascular Biology

Background:

• Neovascularization is a pathological process in retinal vascular disorders such as diabetic retinopathy (DR), age-related macular degeneration (AMD), and retinal vein occlusion (RVO).
• Development of neovascular vessels can lead to severe complications including vitreous hemorrhage, fibrovascular tissue formation, traction retinal detachments, and irreversible vision loss.
• Multiple proangiogenic factors contribute to these complex processes, necessitating therapeutic interventions.

Purpose of the Study:

• To investigate the role of vascular endothelial growth factor (VEGF) in retinal neovascularization.
• To evaluate the current use and long-term safety of anti-VEGF agents in treating retinal vascular disorders.
• To explore the broader landscape of angiogenesis research for novel therapeutic strategies.

Main Methods:

• Review of existing literature on retinal neovascularization and angiogenesis.
• Analysis of the clinical application of anti-VEGF agents for FDA-approved indications and off-label uses.
• Examination of ongoing global research into angiogenic factors and their therapeutic potential.

Main Results:

• Vascular endothelial growth factor (VEGF) is a key factor in retinal neovascularization.
• Anti-VEGF agents are FDA-approved for AMD and RVO and widely used off-label for diabetic macular edema (DME), proliferative DR, and neovascular glaucoma.
• The long-term safety profile of chronic VEGF inhibition remains incompletely evaluated.

Conclusions:

• Anti-VEGF therapy is a significant treatment modality for various retinal vascular diseases.
• Further research is crucial to understand the long-term safety of sustained VEGF inhibition.
• Comprehensive investigation of multiple angiogenic factors holds promise for future retinal disease treatments.